Intellia Therapeutics Inc [NTLA] stock is trading at $10.70, up 11.00%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NTLA shares have gain 9.30% over the last week, with a monthly amount glided 10.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Intellia Therapeutics Inc [NASDAQ: NTLA] stock has seen the most recent analyst activity on January 27, 2025, when Morgan Stanley downgraded its rating to a Equal-Weight and also revised its price target to $11 from $56. Previously, Goldman downgraded its rating to Neutral on February 23, 2024, and dropped its price target to $32. On February 15, 2024, Wolfe Research initiated with a Peer Perform rating. Canaccord Genuity started tracking the stock assigning a Buy rating and suggested a price target of $66 on April 13, 2023. Bernstein initiated its recommendation with a Outperform and recommended $54 as its price target on March 21, 2023. BMO Capital Markets upgraded its rating to Outperform for this stock on March 14, 2023, and upped its price target to $57. In a note dated February 01, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $67 on this stock.
Intellia Therapeutics Inc [NTLA] stock has fluctuated between $8.96 and $34.87 over the past year. Currently, Wall Street analysts expect the stock to reach $39 within the next 12 months. Intellia Therapeutics Inc [NASDAQ: NTLA] shares were valued at $10.70 at the most recent close of the market. An investor can expect a potential return of 264.49% based on the average NTLA price forecast.
Analyzing the NTLA fundamentals
Intellia Therapeutics Inc [NASDAQ:NTLA] reported sales of 43.09M for the trailing twelve months, which represents a drop of -24.02%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -12.48%, Pretax Profit Margin comes in at -12.12%, and Net Profit Margin reading is -12.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.52 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.04 points at the first support level, and at 9.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.15, and for the 2nd resistance point, it is at 11.59.
Ratios To Look Out For
For context, Intellia Therapeutics Inc’s Current Ratio is 6.73. As well, the Quick Ratio is 6.73, while the Cash Ratio is 1.14. Considering the valuation of this stock, the price to sales ratio is 25.29, the price to book ratio is 1.13.
Transactions by insiders
Recent insider trading involved Bhanji Muna, Director, that happened on Jan 29 ’25 when 265.0 shares were sold. VP, Chief Accounting Officer, Dube Michael P completed a deal on Jan 03 ’25 to sell 1372.0 shares. Meanwhile, EVP, General Counsel BASTA JAMES sold 7074.0 shares on Jan 03 ’25.
